Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Lonely Bacteria are More Likely to Become Antibiotic-resistant

Published: Wednesday, April 30, 2014
Last Updated: Wednesday, April 30, 2014
Bookmark and Share
Scientists from the University of Manchester have discovered that microbes in smaller groups are more likely to mutate, resulting in higher rates of antibiotic resistance.

The study, published today in ‘Nature Communications’ and jointly funded by the Wellcome Trust and the Engineering and Physical Sciences Research Council, explored mutation rates in E. coli bacteria.

The researchers found out that the rate of mutation varied according to how many of the bacteria there were. Surprisingly, they discovered that larger groups of bacteria were less likely to mutate than smaller groups.

The more ‘lonely’ bacteria mutated more, and developed greater resistance to the well-known antibiotic Rifampicin, used to treat tuberculosis.

Dr Chris Knight, joint lead author on the study with Dr Rok Krašovec, from the University of Manchester, said: “What we were looking for was a connection between the environment and the ability of bacteria to develop the resistance to antibiotics. We discovered that the rate at which E. coli mutates depends upon how many ‘friends’ it has around. It seems that more lonely organisms are more likely to mutate.”

This change of the mutation rate is controlled by a form of social communication known as quorum sensing – this is the way bacteria let each other know how much of a crowd there is. Quorum sensing involves the release of signalling molecules by bacteria: the denser the population, the more of these molecules released and detected. This helps the bacteria understand their environment and coordinate their behaviour to improve their defence mechanisms and adapt to the availability of nutrients.

Dr Krašovec said: “We were able to change their mutation rates by changing who they shared a test-tube with, which could mean that bacteria manipulate each other’s mutation rates. It also suggests that mutation rates could be affected when bacteria are put at low densities, for instance by a person taking antibiotics.”

The rate of mutation was found to depend on the gene luxS, which is known to be involved in quorum sensing in a wide range of bacteria.

The team now hopes to find ways to control this signalling for medical applications in a future study funded by the Biotechnology and Biological Sciences Research Council.

“Eventually this might lead to interventions to control mutation rates, for instance to minimise the evolution of antibiotic resistance, allowing antibiotics to work better,” said Dr Knight.

Dr Mike Turner, Head of Infection and Immunobiology at the Wellcome Trust, said: “Antibiotic resistance is a real threat to disease control and public health today. Any insight into the origins of such resistance is valuable in the fight to prevent it. Chris Knight and his team have gained a fundamental understanding of bacterial communication and the development of mutations which in the long run could contribute to more potent antibiotics and better control of bacterial disease”.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate Published
Vaccine candidate did not provide statistically-significant protection in preventing TB disease in infants previously vaccinated with BCG.
Monday, February 04, 2013
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos